The abstract reports extraordinary dopamine increases (>500-fold in drug-free patients) but provides no mechanistic explanation for how Atremorine achieves this effect. Understanding these mechanisms is critical for optimizing therapeutic applications and predicting safety profiles. Gap type: unexplained_observation Source paper: Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. (2021, Med Res Rev, PMID:34106485)
Landscape Summary: What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in Parkinson's patients? is a 0.89 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in Parkinson's patients? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: